Marekani - Kiingereza - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil tablets in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil tablets in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the tr

Marekani - Kiingereza - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 125 mg in 5 ml - note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology). cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. the safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of infections other than those specifically listed below have not been established either by adequate and well-controlled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen. - pharyngitis/tonsillitis caused by streptococcus pyogenes. note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefuroxime axetil for oral suspensio

Marekani - Kiingereza - NLM (National Library of Medicine)

direct rx - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bio­equivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology). cefuroxime axetil tablets cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:   - pharyngitis/tonsillitis caused by streptococcus pyoge

Marekani - Kiingereza - NLM (National Library of Medicine)

physicians total care, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.   note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bio­equivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology).   cefuroxime axetil tablets: cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:   1.    pharyngitis/tonsillitis caused

Marekani - Kiingereza - NLM (National Library of Medicine)

rebel distributors corp - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.   note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bio­equivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology).   cefuroxime axetil tablets: cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:   1.    pharyngitis/tonsillitis caused by streptococcus pyogenes.

Marekani - Kiingereza - NLM (National Library of Medicine)

a-s medication solutions - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes. limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae , haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacte

Marekani - Kiingereza - NLM (National Library of Medicine)

sagent pharmaceuticals - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 750 mg - cefuroxime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin structure infections caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes , escherichia coli, klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), streptococcus pneumoniae, escherichia coli, haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - men

Marekani - Kiingereza - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 750 mg - cefuroxime for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae , haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin­-structure infections caused by staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pyogenes , escherichia coli , klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pneumoniae , escherichia coli , haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - mening

Marekani - Kiingereza - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes. limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae , haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacte

Israeli - Kiingereza - Ministry of Health

neopharm (israel) 1996 ltd - cefuroxime as sodium salt - powder for solution or suspension for injection or infusion - cefuroxime as sodium salt 750 mg - cefuroxime - cefuroxime - cefuroxime -fresenius is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth).• community acquired pneumonia• acute exacerbations of chronic bronchitis• complicated urinary tract infections, including pyelonephritis• soft-tissue infections: cellulitis, erysipelas and wound infections• intra-abdominal infections • prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section)• nose infections for example, sinusitis• septic arthritis